Septerna Inc (SEPN)

Currency in USD
35.61
-0.22(-0.62%)
Real-time Data·
SEPN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
34.7536.74
52 wk Range
10.6237.99
Key Statistics
Prev. Close
35.83
Open
35.37
Day's Range
34.75-36.74
52 wk Range
10.62-37.99
Volume
25.46K
Average Volume (3m)
397.78K
1-Year Change
213.9929%
Book Value / Share
8.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SEPN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
45.00
Upside
+26.37%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Septerna Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Neutral

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 45.00
(+26.37% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy40.00+10.96%-Maintain01/07/2026
Guggenheim
Buy45.00+24.83%52.00Maintain01/07/2026
Truist Securities
Buy43.00+19.28%35.00Maintain01/07/2026
Guggenheim
Buy52.00+44.24%-New Coverage11/06/2026
Raymond James
Buy53.00+47.02%47.00Maintain08/06/2026

Earnings

Latest Release
11/05/2026
EPS / Forecast
-0.19 / -0.74
Revenue / Forecast
26.52M / --
EPS Revisions
Last 90 days

SEPN Income Statement

Compare SEPN to Peers and Sector

Metrics to compare
SEPN
Peers
Sector
Relationship
P/E Ratio
−44.8x−5.8x−0.4x
PEG Ratio
−0.570.050.00
Price/Book
4.3x5.2x2.6x
Price / LTM Sales
22.4x30.8x3.0x
Upside (Analyst Target)
20.0%29.3%49.7%
Fair Value Upside
Unlock−9.1%7.3%Unlock

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.91M15.33%231.24M
Other Institutional Investors
65.20M84.67%2.18B
Public Companies & Retail Investors
0.000.00%0.00
Total
72.11M100.00%2.41B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Third Rock Ventures, LLC23.13%10,427,250349,000
RA Capital Management, L.P.15.52%6,995,858234,151

People Also Watch

27.85
ZBIO
+0.61%
62.93
MBX
+1.50%
30.90
ALMS
+5.57%
142.17
ABVX
-1.26%

FAQ

What Is the Septerna (SEPN) Stock Price Today?

The Septerna stock price today is 35.61 USD.

What Stock Exchange Does Septerna Trade On?

Septerna is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Septerna?

The stock symbol for Septerna is "SEPN."

What Is the Septerna Market Cap?

As of today, Septerna market cap is 1.61B USD.

What Is Septerna's Earnings Per Share (TTM)?

The Septerna EPS (TTM) is -0.81.

When Is the Next Septerna Earnings Date?

Septerna will release its next earnings report on 17/08/2026.

From a Technical Analysis Perspective, Is SEPN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Septerna Stock Split?

Septerna has split 0 times.

How Many Employees Does Septerna Have?

Septerna has 130 employees.

What is the current trading status of Septerna (SEPN)?

As of 08/07/2026, Septerna (SEPN) is trading at a price of 35.61 USD, with a previous close of 35.83 USD. The stock has fluctuated within a day range of 34.75 USD to 36.74 USD, while its 52-week range spans from 10.62 USD to 37.99 USD.

What Is Septerna (SEPN) Price Target According to Analysts?

The average 12-month price target for Septerna is 45.00 USD, with a high estimate of 60 USD and a low estimate of 38 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +26.37% Upside potential.

What Is the SEPN After Hours Price?

SEPN's last after hours stock price is 36.50 USD, the stock has decreased by 0.67, or 1.87%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.